Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Multicenter, Placebo-controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of Obeticholic Acid in Patients With Primary Biliary Cholangitis

NCT05450887 is registered in ClinicalTrials.gov with Nanjing Chia-tai Tianqing Pharmaceutical as lead sponsor.

NCT NCT05450887
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05450887 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Multicenter, Placebo-controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of Obeticholic Acid in Patients With Primary Biliary Cholangitis
Lead sponsor
Nanjing Chia-tai Tianqing Pharmaceutical
Phase
Phase 3
Overall status
Completed
Start date
September 23, 2021
Completion date
April 9, 2024
Enrollment
108 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

primary biliary cholangitis